Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024 07:13 ET
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Huize Holding Limited Files 2023 Annual Report on Form 20-F
April 19, 2024 07:11 ET
|
Huize Holding Limited
SHENZHEN, China, April 19, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize,” the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Balchem Corporation Announces Quarterly Conference Call for First Quarter Financial Results on May 3, 2024
April 19, 2024 07:00 ET
|
Balchem Corporation
MONTVALE, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, May 3, 2024, at 11:00 AM Eastern Time (ET) to...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
April 19, 2024 06:10 ET
|
Alvotech
Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Himax Joins Forces with E Ink to Revolutionize Smart Retail with Premier of WiseEye™ AI at 2024 Touch Taiwan
April 19, 2024 04:45 ET
|
Himax Technologies, Inc.
TAINAN, Taiwan and HSINCHU, Taiwan, April 19, 2024 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers...
Cumulus Media Announces Amendment and Extension of Withdrawal Deadline and Expiration Time for Exchange Offer and Consent Solicitation
April 18, 2024 21:39 ET
|
Cumulus Media Inc.
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ: CMLS) (the “Company” or “Cumulus”) today announced that its subsidiary, Cumulus Media New Holdings Inc. (the “Issuer”), has...